A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85724-5023, United States
La Jolla, California 92037, United States
Sacramento, California 95817, United States
New Haven, Connecticut 06510, United States
Palm Beach Gardens, Florida 33418, United States
Tampa, Florida 33613, United States
Kansas City, Missouri 64111, United States
New Hyde Park, New York 11040, United States
Rochester, New York 14620, United States
Cleveland, Ohio 44120, United States
Madison, Wisconsin 53705, United States
Homburg/Saar, Saarland 66421, Germany